TCGA-D8-A27I-01A-11R-A16F-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 15
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- ANGIOGENESIS+0.420
- TNFA_SIGNALING_VIA_NFKB+0.420
- HEDGEHOG_SIGNALING+0.410
- UV_RESPONSE_DN+0.410
- WNT_BETA_CATENIN_SIGNALING+0.410
- KRAS_SIGNALING_UP+0.350
- INFLAMMATORY_RESPONSE+0.320
- MYOGENESIS+0.320
- TGF_BETA_SIGNALING+0.310
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.590
- MYC_TARGETS_V1-0.520
- MYC_TARGETS_V2-0.520
- MTORC1_SIGNALING-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- DNA_REPAIR-0.370
- SPERMATOGENESIS-0.340
- INTERFERON_ALPHA_RESPONSE-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0DV-01A-21R-A12P-07 | — | A | 0.937 |
| 2 | TCGA-A2-A0CZ-01A-11R-A034-07 | — | A | 0.930 |
| 3 | TCGA-BH-A0DP-01A-21R-A056-07 | — | A | 0.929 |
| 4 | TCGA-A2-A0EW-01A-21R-A115-07 | — | A | 0.929 |
| 5 | TCGA-AC-A3HN-01A-11R-A213-07 | — | A | 0.926 |
| 6 | TCGA-56-A4ZJ-01A-11R-A262-07 | — | cohortSQ1 | 0.925 |
| 7 | SRR35579845 | — | A | 0.923 |
| 8 | TCGA-LL-A440-01A-11R-A24H-07 | — | A | 0.920 |
| 9 | SRR1313091 | — | A | 0.918 |
| 10 | TCGA-BH-A0DE-01A-11R-A115-07 | — | A | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |